For the trial’s first part, 96 participants will be enrolled at four centres in the us. This echoes results from vaxart's phase 2.
“the [december read] will be our first immunogenicity data in humans, and it is an important card to turn over,” chief business officer samuel wu told this news service.
Vaxart covid vaccine news. This study used the same vaccine candidate vaxart is using in its development of an oral tablet vaccine,” added dr. South san francisco, ca, usa i october 26, 2021 i vaxart, inc. Nonetheless, the company in june issued a news release that stated:
South san francisco, ca, usa i october 6, 2021 i vaxart, inc. Vaxart expects to begin dosing the first of 96 u.s. In more positive news for the company, a recent study in hamsters showed its vaccine candidate reduces airborne transmission of coronavirus.
The company expects to enroll 96 subjects at four sites in the u.s. Ocgn), it has a lot more going for it. Vaxart garnered attention from investors in the early days of the covid pandemic as it applied its technology behind an influenza vaccine program to the coronavirus.
Vaxart expects to enroll 96. Vaxart expects to begin dosing the first of 96 u.s. South san francisco, calif., oct.
Plus, the company is in a solid (albeit not perfect) financial position. That sent shares of the company. South san francisco, calif., oct.